Cancer Research Technology
Log in Register
Menu

Anti-Keratin14 [LL002]

Invented by Prof Birgit Lane at Queen Mary University of London

Info

Catalogue Number 151441
Applications FACS IHC IF WB
Antigen/Gene or Protein Targets Keratin 14
Reactivity Human, Mouse and Pig
Relevance Monoclonal antibody directed keratin 14, with use in identifying squamous cell carcinoma, and distinguishing basal breast carcinomas.

Background and Research Application
Keratin 14, a type 1 intermediate filament protein, is one of the two keratins alongside keratin 5 which distinguish stratifying epithelial cell types from simple epithelial cell types.
LL002 antibody therefore characterises stratifying/keratinocyte cell types. This is useful for the identification of squamous cell carcinomas, and as a prognostic marker in breast carcinoma. LL002 labels the basal layer of stratifying squamous and non-squamous epithelia, with a cytoplasmic staining pattern. This can help distinguish between basal and non-basal subtypes of breast carcinomas.
Host Mouse
Immunogen The last 16 carboxy-terminal amino acids of human keratin, in the form of a synthetic peptide. This was coupled to thyroglobulin by the extra Cys added at the N terminus.
Immunogen UniProt ID P02533
Subclass IgG3
Molecular Weight (kDa) 50
Myeloma Used Sp2/0-Ag14
Recommended Growing Conditions DMEM + 5% FCS
Strain Balb/c
Notes Production Details
Purified using multi-step affinity chromatography with protein A.

Storage Conditions
Store at -20 degrees frozen. Avoid repeated freeze/thaw cycles.

Points of Interest
Anti-keratin14 did not stain the transitional epithelium including the prostatic part of the urethra. This antibody has also proved a good marker for differentiation of intraductal from invasive salivary duct carcinoma by the positive staining of basal cells surrounding the in-situ neoplasm alongside differentiation of benign prostate from prostate carcinoma.

Concentration
1mg/ml as standard
Research Area Cell Signaling & Signal Transduction

References

There are 11 reference entries for this reagent.

View All References

References: 11 entries

Hagiyama et al. 2017. Front Physiol. 8:997. PMID: 29259558.

Kuga et al. 2016. Sci Rep. 6:26557. PMID: 27222304.

Haikala et al. 2016. Cell Cycle. 15(3):316-23. PMID: 26873145.

Bohn et al. 2010. Int J Clin Exp Pathol. 3(6):600-7. PMID: 20661408.

p16INK4a expression in basal-like breast carcinoma.

Europe PMC ID: 20661408

Kurzrock et al. 2008. Am J Physiol Renal Physiol. 294(6):F1415-21. PMID: 18367656.

Label-retaining cells of the bladder: candidate urothelial stem cells.

Europe PMC ID: 18367656

Purkis et al. 1990. J Cell Sci. 97 ( Pt 1):39-50. PMID: 1701769.

Antibody markers of basal cells in complex epithelia.

Europe PMC ID: 1701769

Schaafsma et al. 1990. Am J Pathol. 136(2):329-43. PMID: 1689541.

Distribution of cytokeratin polypeptides in human transitional cell carcinomas, with special emphasis on changing expression patterns during tumor progression.

Europe PMC ID: 1689541


Add a reference

References: 11 entries

Hagiyama et al. 2017. Front Physiol. 8:997. PMID: 29259558.

Kuga et al. 2016. Sci Rep. 6:26557. PMID: 27222304.

Haikala et al. 2016. Cell Cycle. 15(3):316-23. PMID: 26873145.

Bohn et al. 2010. Int J Clin Exp Pathol. 3(6):600-7. PMID: 20661408.

p16INK4a expression in basal-like breast carcinoma.

Kurzrock et al. 2008. Am J Physiol Renal Physiol. 294(6):F1415-21. PMID: 18367656.

Label-retaining cells of the bladder: candidate urothelial stem cells.

Purkis et al. 1990. J Cell Sci. 97 ( Pt 1):39-50. PMID: 1701769.

Antibody markers of basal cells in complex epithelia.

Schaafsma et al. 1990. Am J Pathol. 136(2):329-43. PMID: 1689541.

Distribution of cytokeratin polypeptides in human transitional cell carcinomas, with special emphasis on changing expression patterns during tumor progression.


Add a reference

Inventor Information